This content is from: Premium

Jeffrey Ubben’s ValueAct Continues to Surge Despite its Valeant Stake

The activist firm’s flagship hedge fund is still up for the year despite still holding shares of the embattled drugmaker.

  • By Stephen Taub

      Valeant Pharmaceuticals International headquarters (photo credit: Ron Antonelli/Bloomberg)Who says you can’t make money if you are all in on Valeant Pharmaceuticals International? While hedge funds managed by Bill Ackman’s Pershing Square Capital Management and John Paulson’s Paulson & Company have suffered sharp losses in the past year or two in part

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content